A new era in the management of pulmonary arterial hypertension related to scleroderma: Endothelin receptor antagonism

Annals of the Rheumatic Diseases

Volumn 63, Issue 9, 2004, Pages 1009-1014

  Hachulla, E ^a   Coghlan, J G ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIURETIC AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SITAXSENTAN; UNIPROST; VASODILATOR AGENT;

AMINOTRANSFERASE BLOOD LEVEL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG EFFICACY; DYSPNEA; EARLY DIAGNOSIS; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; HEART DISEASE; HUMAN; NONHUMAN; OXYGEN THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SIDE EFFECT; SYNDROME CREST;

EID: 4344697343     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.017673     Document Type: Review

References (57)

1. Denton CP, Black CM. Scleroderma and related disorders: therapeutic aspects. Baillieres Best Pract Res Clin Rheumatol 2000;14:17-35.
2. Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. Intern Med 1994;33:579-82.
3. Galiè N, Manes A, Uguccioni L, Serafini F, De Rosa M, Branzi A, et al. Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest 1998;114:184-94S.
4. Vlachoyiannopoulos P, Dafni U, Pakas I, Spyropoulou-Vlachou M, Stavropoulos-Giokas C, Moutsopoulos HM. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000;59:359-67.
5. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
6. Kim NHS, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Therapeut 2002;7:9-19.
7. Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002;11:991-1002.
8. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
9. Medsger TA, Masi AT. The epidemiology of systemic sclerosis. Ann Intern Med 1971;74:714-21.
10. Abu-Shakra M, Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 1995;22:2100-2.
11. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-48.
12. Bryan C, Howard Y, Brenn P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1122-6.
13. Battle RW, Davitt MA, Cooper SM, Buckley LM, Leib ES, Beglin PA, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-19.
14. Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003;42:71-5.
15. Masi AT, Rodnan GP, Medsger TA Jr, Altman RD, D'Angelo WA, Fries JF, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
16. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
17. Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998;17:48-54.
18. Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J 2002;19:571-6.
19. Tilton RG, Brock TA, Dixon RAF. Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. Expert Opin Investig Drugs 2001;10:1291-308.
20. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-25.
21. Gibbs JSR, Higenbottam T. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86(Suppl 1):i1-13.
22. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis 1988;31:205-38.
23. Rich S, ed. Primary pulmonary hypertension: executive summary from the World Health Organisation, 1998. http://www.who.int/ncd/cvd/.
24. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Du Bais RM. Comparison of Doppler echocardiography and right heart catheterisation to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-43.
25. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15.
26. Maeda M, Kachi H, Takagi H, Kitajima Y. Is there circadian variation of plasma endothelin (ET-1) in patients with systemic scleroderma (SSc)? J Dermatol Sci 1997;16:38-44.
27. Kazzam E, Waldenstrom A, Hedner T, Hedner J, Caidahl K. Endothelin may be pathogenic in systemic sclerosis of the heart. Int J Cardiol 1997;60:31-9.
28. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localisation of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268-76.
29. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
30. Yamane K, Miyaucni T, Suzuki N, Yuhara T, Akama T, Suzuki H, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992;19:1566-71.
31. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis:an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
32. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;23:344-50.
33. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167:580-6.
34. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
35. Launay D, Hachulla E, Hatron PY, Michon-Pasturel U, Hebbar M, Queyrel V, et al. Pulmonary hypertension screening in systemic scleroderma: a cohort study of 67 patients. Rev Med Interne 2001;22:819-29.
36. Sanchez O, Nunes H, Sitbon O, Garcia G, Simonneou G, Humbert M. Pulmonary hypertension associated with systemic sclerosis. Ann Med Interne 2002;153:250-9.
37. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003;62:97-9.
38. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
39. Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999;54:273-7.
40. Sitbon O, Humbert M, Ragot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safety identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
41. Sanchez O, Humbert M, Sitbon O, Nunes G, Garcia G, Simonneau G. Pulmonary hypertension in connective tissue disease. Rev Med Interne 2002;23:41-54.
42. Chatterjee K, De Marco T, Alpert JS. Pulmonary hypertension: haemodynamic diagnosis and management. Arch Intern Med 2002;162:1925-33.
43. Schachna L, Braunstein N, Dauber J, Wigley F, Medsger Jr T, White B, et al. Lung transplantation for systemic sclerosis compared with idiopathic pulmonary fibrosis: increased early mortality but comparable survival at one year [abstract]. Arthritis Rheum 2002;46(suppl):S382.
44. Badesch DB, Tapson VE, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomised controlled trial. Ann Intern Med 2000;132:425-34.
45. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
46. Simonneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomised, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
47. Galiè N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue in patients with pulmonary arterial hypertension: a randomised, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502.
48. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2000;161:487-92.
49. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
50. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
51. Badesch DB, Bodin F, Channick RN, Frost A, Rainisio M, Robbins IV, et al. Complete results of the first randomised, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Curr Tiber Res Clin Exp 2002;63:227-46.
52. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-6.
53. Denton CP, Black CM, for the 351 and BREATHE-1 Study Group. Bosentan for scleroderma associated pulmonary hypertension. A subgroup analysis of two controlled trials [abstract]. Arthritis Rheum 2003;48(suppl):S456.
54. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31.
55. McLaughlin V, Sitbon O, Rubin LJ, Levy P, Barst R, Badesch D, et al. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension [abstract]. Am J Respir Crit Care Med 2003;167(suppl):A441.
56. Black CM, Korn J, Mayes M, Matucci-Cerinic M, for the RAPIDS-1 Study Group. Improvement in the net ulcer burden and hand functionality in patients with digital ulcers related to systemic sclerosis [abstract]. Arthritis Rheum 2003;48(suppl):S454.
57. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.